Phaseline

Companies › BeBetter Med

BeBetter Med: clinical trials, targets and expected readouts

5 active drug programs in 7 registered trials: 3 Phase 2, 2 Phase 3, 2 Phase 1; Oncology, Cardiovascular; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ifupinostat Hydrochloride for Injection (BEBT-908)
Histone deacetylase (HDAC) inhibitor
HDACPhase 3Relapsed/Refractory Diffuse Large B-Cell LymphomaDec 2028
BEBT-209–Phase 3HR+/HER2- Locally Advanced, Metastatic Breast Cancer; Locally Advanced Triple-negative Breast CancerJun 2030
BEBT-109
EGFR exon 20 insertion inhibitor
EGFRPhase 2Non-Small Cell Lung Cancer; Non Small Cell Lung CancerJun 2027
BEBT-507 Injection–Phase 1Polycythemia VeraJan 2028
BEBT-701 Injection–Phase 1Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein CholesterolNov 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06706713BEBT-109Phase 2Non-Small Cell Lung CancerOncologyDec 2025
NCT06998108BEBT-209Phase 3HR+/HER2- Locally Advanced, Metastatic Breast CancerOncologyDec 2025
NCT06514027BEBT-109Phase 2Non Small Cell Lung CancerOncologyJun 2027
NCT07012109BEBT-507 InjectionPhase 1Polycythemia VeraOncologyJan 2028
NCT07368608BEBT-701 InjectionPhase 1Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein CholesterolCardiovascularNov 2028
NCT06792253Ifupinostat Hydrochloride for Injection (BEBT-908)Phase 3Relapsed/Refractory Diffuse Large B-Cell LymphomaOncologyDec 2028
NCT07544056BEBT-209Phase 2Locally Advanced Triple-negative Breast CancerOncologyJun 2030

Targets

EGFR (1) HDAC (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group

Companies built like this

Jiangsu Alphamab Biopharmaceuticals Nanjing Sanhome Pharmaceutical Jiangsu Aosaikang Pharmaceutical ArriVent BioPharma Wayshine Biopharm

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.